Protagenic Therapeutics (PTIX) and Phytanix Bio said Monday that they have agreed to combine in an all-stock deal.
The combined entity will be called Phytanix Inc. and will bring together two pipelines focused on stress-related and central nervous system disorders, five preclinical assets, and one clinical-stage asset, the companies said.
The combined company will be 35% owned by pre-combination Protagenic stockholders and 65% owned by Phytanix Bio stockholders after the merger, the companies said.
Shares of Protagenic were up 99% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.